Stock analysts at Piper Jaffray Companies began coverage on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a research report issued to clients and investors on Monday. The brokerage set an “overweight” rating and a $14.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective suggests a potential upside of 108.64% from the stock’s current price.

Several other brokerages have also recently commented on TTPH. BMO Capital Markets reissued an “outperform” rating and issued a $13.00 price target (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, July 26th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. BidaskClub raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $8.00 to $15.00 in a research note on Wednesday, July 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $11.21.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.71 on Monday. The stock’s market capitalization is $342.57 million. The firm’s 50-day moving average is $6.56 and its 200-day moving average is $7.09. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. During the same period last year, the firm earned ($0.47) EPS. The company’s revenue was up 28.2% compared to the same quarter last year. On average, equities research analysts predict that Tetraphase Pharmaceuticals will post ($2.54) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Initiates Coverage on Tetraphase Pharmaceuticals, Inc. (TTPH)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/30/piper-jaffray-companies-initiates-coverage-on-tetraphase-pharmaceuticals-inc-ttph.html.

In related news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the sale, the insider now owns 17,500 shares of the company’s stock, valued at approximately $105,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 5.50% of the company’s stock.

A number of large investors have recently bought and sold shares of TTPH. Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after buying an additional 6,114 shares during the period. Vanguard Group Inc. raised its stake in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares during the period. State Street Corp raised its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares during the period. Geode Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 17.0% in the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after buying an additional 45,554 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 408,078 shares during the period. Hedge funds and other institutional investors own 41.73% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.